Biology Reference
In-Depth Information
Bebia Z, Buch SC, Wilson JW et al (2004) Bioequivalence revisited:influence of age and sex on
CYP enzymes. Clin Pharmacol Ther 76:618-627
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to
clinical use. Pharmacol Rev 58:488-520
Bethke Th, Hartmann M, Baumgartner A, Eichberger C, Hauns B, Wurst W (2001a) The new
PDE4 inhibitor roflumilast does not influence cardiovascular function. Am J Respir Crit Care
Med 163(5):A431
Bethke Th, H
unnemeyer A, Hauns B, Diedrich A, Baumgartner A, Eichberger C, Drollmann A,
Hartmann M, Neuhauser M, David M, Zech K, Wurst W (2001b) Smoking has no effect on the
pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor. Eur Respir
J Suppl 18(33):156s, P1061
Bethke TD, Hauns B, Zech K, David M, Wurst W (2002a) Dose linearity of roflumilast, a new
selective PDE4 inhibitor. Am J Respir Crit Care Med 165:A595
Bethke T, Hartmann M, Zech K, David M, Weimar C, Wurst W (2002b) No dose adjustment
of roflumilast in patients with severe renal impairment. Am J Respir Crit Care Med 165:
A594
Bethke TD, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Hauschke D, David M, Lahu G,
Zech K, Hermann R, Siegmund W (2006) Roflumilast, a once-daily oral phosphodiesterase 4
inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when
co-administered in healthy subjects. Int J Clin Pharmacol Ther 44:572-579
Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K, David M, Knoerzer D,
Wurst W, Gleiter CH (2007) Dose-proportional intraindividual single- and repeated-dose
pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin
Pharmacol 47:26-36
Bethke TD, Lahu G (2011) High absolute bioavailability of the new oral phosphodiesterase
4 inhibitor roflumilast. Int J Clin Pharmacol Ther 49:51-58
Bethke TD, H
€
unnemeyer A, Lahu G, Lemmer B (2010) Chronopharmacology of roflumilast:
a comparative pharmacokinetic study of morning vs. evening administration in healthy adults.
Chronobiol Int 27:1843-1853
Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF,
St
€
urzebecher CS, Martin R (2009) Treatment with the phosphodiesterase type-4 inhibitor
rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult Scler
15:1206-1214
€
B
unnemeyer A, Lahu G, Gleiter CH, Bethke TD (2011) Theophylline and in healthy
adults. Br J Clin Pharmacol (in press)
Boswell-Smith V, Cazzola M, Page CP (2006) Are phosphodiesterase 4 inhibitors just more
theophylline? J Allergy Clin Immunol 117:1237-1243
Boswell-Smith V, Spina D (2007) PDE4 inhibitors as potential therapeutic agents in the treatment
of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2:121-129
Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in
airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp
Ther 297:280-290
Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M,
Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodi-
esterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat
Biotechnol 28:63-70
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2-124 and
M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary
disease: two randomised clinical trials. Lancet 374:685-694
Calverley PMA, Martinez FJ, Goehring UM, Rennard SI (2010) Defining patient populations
in COPD: experience with roflumilast. Presented at: 7
th
International Multidisciplinary
Conference on Chronic Obstructive Pulmonary Disease (COPD7), Birmingham, UK, 30
June-2 July 2010 (Poster 48)
€
ohmer G, H
€
